Skip to Main Content
Table III.

Modulation of EAE by α-GalCer in C57BL/6 and C57BL/6.CD1d−/− Mice


Treatment

No. animals with
 EAE/total no. of animals
 (individual maximal score)

Mean disease score

Mean day of onset
C57BL/6 mice    
Vehicle/PBS 9/10 (5,5,4,4,4,4,3,1,1,0) 3.1 14.4 
Coimmunization with α-GalCer 2/10 (2,1,0,0,0,0,0,0,0,0) 0.3 13.5 
C57BL/6.CD1d−/− mice    
Vehicle/PBS 10/12 (4,3,3,3,3,2,2,2,1,1,0,0) 2.0 14.9 
Coimmunization with α-GalCer
 
7/8 (4,3,2,2,2,2,1,0)
 
2.0
 
16.6
 

Treatment

No. animals with
 EAE/total no. of animals
 (individual maximal score)

Mean disease score

Mean day of onset
C57BL/6 mice    
Vehicle/PBS 9/10 (5,5,4,4,4,4,3,1,1,0) 3.1 14.4 
Coimmunization with α-GalCer 2/10 (2,1,0,0,0,0,0,0,0,0) 0.3 13.5 
C57BL/6.CD1d−/− mice    
Vehicle/PBS 10/12 (4,3,3,3,3,2,2,2,1,1,0,0) 2.0 14.9 
Coimmunization with α-GalCer
 
7/8 (4,3,2,2,2,2,1,0)
 
2.0
 
16.6
 

Groups of age-matched mice were subcutaneously immunized with 300 μg of MOG35–55 emulsified in CFA and at the same time administered with 4.4 μg of α-GalCer in vehicle or with the vehicle only, as described in Materials and Methods. Clinical symptoms of EAE were monitored daily.

Close Modal

or Create an Account

Close Modal
Close Modal